Last reviewed · How we verify
Amikellin — Competitive Intelligence Brief
phase 2
khellin
Cytochrome P450 1A1
Metabolic
Small molecule
Live · refreshed every 30 min
Target snapshot
Amikellin (KHELLIN). Khellin works by inhibiting the Cytochrome P450 1A1 enzyme, which plays a role in the metabolism of certain substances in the body.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Amikellin TARGET | KHELLIN | phase 2 | khellin | Cytochrome P450 1A1 | ||
| Heraclin | BERGAPTEN | phase 3 | bergapten | Taste receptor type 2 member 10, Cytochrome P450 1A1, Amine oxidase [flavin-containing] A |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (khellin class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Amikellin CI watch — RSS
- Amikellin CI watch — Atom
- Amikellin CI watch — JSON
- Amikellin alone — RSS
- Whole khellin class — RSS
Cite this brief
Drug Landscape (2026). Amikellin — Competitive Intelligence Brief. https://druglandscape.com/ci/khellin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing